WPI 844 (Glipizide extended release 5 mg)
Pill imprint WPI 844 has been identified as Glipizide extended release 5 mg.
Glipizide is used in the treatment of diabetes, type 2 and belongs to the drug class sulfonylureas. Risk cannot be ruled out during pregnancy. Glipizide 5 mg is not a controlled substance under the Controlled Substance Act (CSA).
- WPI 844
- 5 mg
- 6.00 mm
- Prescription only
- Drug Class:
- Pregnancy Category:
- C - Risk cannot be ruled out
- CSA Schedule:
- Not a controlled drug
- Watson Laboratories, Inc.
- National Drug Code (NDC):
- Inactive Ingredients:
- acetyltributyl citrate
hydroxyethyl cellulose (2000 mpa.s at 1%)
hydroxypropyl cellulose (type h)
methacrylic acid - methyl methacrylate copolymer (1:1)
FD&C Yellow No. 6
Note: Inactive ingredients may vary.
|NDC Code||Manufacturer / Repackager|
|68084-0111||Amerisource Health Services|
|10370-0190||Anchen Pharmaceuticals, Inc|
|54569-5547||A-S Medication Solutions, LLC (repackager)|
|54868-5210||Physicians Total Care Inc (repackager)|
More about glipizide
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Images
- Drug Interactions
- Support Group
- Pricing & Coupons
- En Español
- 35 Reviews – Add your own review/rating
- Drug class: sulfonylureas
Related treatment guides
Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Copyright 2017 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.